Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme

Targeted Oncology

Volumn 9, Issue 4, 2014, Pages 395-398

  Mansour, Joshua ^a   Fields, Braxton ^a   Macomson, Samuel ^a   Rixe, Olivier ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Bevacizumab; Glioblastoma multiforme; Pineal gland

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DACARBAZINE; MONOCLONAL ANTIBODY;

AGED; ANASTOMOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DIPLOPIA; DRUG EFFICACY; GAIT DISORDER; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERTENSION; LUPUS VULGARIS; MALE; MEDICAL HISTORY; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; OUTCOME ASSESSMENT; PINEAL BODY TUMOR; RARE DISEASE; TUMOR BIOPSY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; DISEASE COURSE; FATALITY; PATHOLOGY; PINEAL BODY; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; FATAL OUTCOME; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PINEAL GLAND; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84940291292     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0327-8     Document Type: Article

References (21)

1. Birbilis TA, Matis GK, Eleftheriadis SG et al (2010) Spinal metastasis of glioblastoma multiforme. Spine 35(7):264–269
2. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 1:97–109
3. Gasparetto EL, Warszawiak D, Adam GP et al (2003) Glioblastoma multiforme of the pineal region: case report. Neuro-Psiquitar 61(2B):468–472
4. Edwards MSB, Hudgins RJ, Wilson CB et al (1988) Pineal region tumors in children. J Neurosurg 68:689–697
5. Stupp R, Mason WP, van der Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96
6. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–66
7. Malstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractioned radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol 13(9):916–926
8. Gil-Gil MJ, Mesia C, Rey M, Bruna (2013) Bevacizumab for the treatment of glioblastoma. Clin Med Insights Onc 7:123–135
9. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–9
10. Gilbert MR, Dignam J, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed Glioblastoma. N Engl J Med 370:699–708
11. Henriksson R, Bottomley A, Mason W et al (2013) Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31 Suppl (abstr 2005)
12. Taal W, Oosterkamp HM, Walenkamp A et al (2013). A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31, 2013 Suppl (abstr 2001)
13. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-oncology working group. J Clin Oncol 28(11):1963–1972
14. Amini A, Schmidt RH, Salzman KL et al (2006) Glioblastoma multiforme of the pineal region. J Neurooncol 79:307–14
15. Chamberlain MC, Glantz MJ, Chamlmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83
16. Brandes A, Tosoni A, Spagnolli F et al (2007) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro-Oncology 10:361–367
17. Verhoeff JJ, van Tellingen O, Claes A et al (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444
18. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638
19. Wick W, Wick A, Weiler M, Weller M (2011) Patterns of progression in malignant glioma following anti-VEGF therapy; perceptions and evidence. Curr Neurol Neurosci Rep 11(3):305–312
20. Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevaczumab for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–95
21. Johnson DR, Leeper HE, Uhm JH (2013) Glioblastoma survival in the Unites States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer. doi:10.1002/cncr.28259